A woman with long hair reads a book on a sunlit windowsill.

Gaucher Disease Treatments Compared

Name: Gaucher Disease Treatments Compared
Creator: Jason Hunter
Published: 2026-10-12

5 FDA-approved drugs and 1 in development, side by side from the current prescribing labels. Newest label Aug 2026. Checked October 12, 2026.

Enzyme replacement infusionsCerezyme · VPRIV · Elelyso

Substrate reduction pillsCerdelga · Zavesca

Five drugs are FDA approved for Gaucher disease. Cerezyme, VPRIV and Elelyso are enzyme replacement infusions given every 2 weeks, and each carries a boxed warning for severe allergic reactions. Cerdelga and miglustat (sold as Zavesca and as generics) are pills that slow the making of the fatty substance that builds up; Cerdelga needs a CYP2D6 gene test first, and miglustat is only for adults who cannot have enzyme replacement. Cerezyme is the only one whose label covers type 3, and only for symptoms outside the brain. Venglustat, a pill designed to reach the brain in type 3, faces an FDA decision on November 25, 2026.

Side by side

5 approved Gaucher disease treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

Gaucher Disease treatments compared: route, schedule, approved use and approval date
Drug	How it is given	How often	Approved for	First approved
Cerezyme imiglucerase Sanofi (Genzyme)	IV infusion, usually every 2 weeks, started in a healthcare settingAbout 90 minutes per dose	Dose set by the doctor between 2.5 units/kg 3 times a week and 60 units/kg every 2 weeks; each infusion runs 1 to 2 hours (2 hours for children 20 kg or under)	Adults and children with type 1 Gaucher disease, and the symptoms of type 3 outside the brain and nervous system	May 23, 1994
VPRIV velaglucerase alfa Takeda	IV infusion over 60 minutes every 2 weeks, started in a healthcare settingAbout 60 minutes per dose	60 units/kg every 2 weeks for people new to treatment; people switching from Cerezyme keep their Cerezyme dose and start 2 weeks after their last Cerezyme infusion	Long-term treatment of type 1 Gaucher disease; dosing is set out for age 4 and older	February 26, 2010
Elelyso taliglucerase alfa Pfizer	IV infusion over 60 to 120 minutes every 2 weeks, started in a healthcare settingAbout 90 minutes per dose	60 units/kg every 2 weeks for people new to treatment; people switching from Cerezyme start at their Cerezyme dose	People 4 and older with a confirmed diagnosis of type 1 Gaucher disease	May 1, 2012
Cerdelga eliglustat Sanofi (Genzyme)	Capsule by mouth once or twice a day, depending on a CYP2D6 gene test	84 mg twice a day for extensive and intermediate metabolizers, 84 mg once a day for poor metabolizers; swallow whole and avoid grapefruit	Adults with type 1 Gaucher disease whose CYP2D6 gene test shows they are an extensive, intermediate or poor metabolizer	August 19, 2014
Zavesca miglustat (generics available, including Yargesa) Actelion (Johnson & Johnson); generics from several makers	Capsule by mouth 3 times a day	100 mg 3 times a day at regular times; may be lowered to once or twice a day for tremor or diarrhea; lower starting doses with kidney impairment	Adults with mild to moderate type 1 Gaucher disease for whom enzyme replacement is not an option, for example because of allergy or poor vein access	July 31, 2003

The calendar

A year on each Gaucher disease treatment

Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.

Cerezyme

Infusion, at a clinic

26 doses a year

VPRIV

Infusion, at a clinic

26 doses a year

Elelyso

Infusion, at a clinic

26 doses a year

Cerdelga

By mouth, at home

730 doses a year

Zavesca

By mouth, at home

1095 doses a year

Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.

The evidence

What the pivotal Gaucher disease trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

Before you compare

How to read the Gaucher disease trial results

1
Your Gaucher type narrows the list
All 5 drugs are approved for type 1. Only Cerezyme's label also covers type 3, and only for symptoms outside the brain and nervous system. None of the 5 treats brain symptoms, which is the gap venglustat is being reviewed to fill.
2
Cerdelga starts with a gene test
A CYP2D6 gene test decides whether Cerdelga can be used and how often: twice a day for extensive and intermediate metabolizers, once a day for poor metabolizers. Ultra-rapid metabolizers may not reach a working level. Many other medicines and liver problems rule it out, and grapefruit should be avoided.
3
Switching infusions is built into the labels
The VPRIV and Elelyso labels both describe switching people who are stable on Cerezyme at the same dose. VPRIV starts 2 weeks after the last Cerezyme infusion. Each infusion is started in a healthcare setting with emergency equipment because of the boxed allergy warning.
4
The trial results are not a ranking
Each pivotal trial was small, 25 to 40 people, and measured something different: hemoglobin for VPRIV, spleen size for Elelyso and Cerdelga, a comparison with an older enzyme for Cerezyme, and no comparison group at all for miglustat. The numbers in the table show what each drug did in its own trial, not which works best.

Gaucher Disease pivotal trial results by drug
Drug	Pivotal trial	Primary result
Cerezyme imiglucerase Sanofi (Genzyme)	Study 1, 30 people 12 and older with type 1, 6 months, against the older enzyme alglucerase	Hemoglobin up 1.9 g/dL vs 1.6 on alglucerase, and spleen 35% smaller vs 30%; a registry study of 1,052 people with type 1 and 118 with type 3 also showed gains
VPRIV velaglucerase alfa Takeda	Study I, 25 people 4 and older new to treatment, 12 months; Study II, 34 people, 9 months, against Cerezyme	Hemoglobin up 2.4 g/dL after 12 months at 60 units/kg in Study I
Elelyso taliglucerase alfa Pfizer	Trial 1, 31 adults new to treatment with enlarged spleens and low platelets, 9 months	Spleen size fell from 16.7 to 10.4 times normal on average at the recommended 60 units/kg dose
Cerdelga eliglustat Sanofi (Genzyme)	Trial 1 (ENGAGE), 40 people 16 and older new to treatment, 9 months, against placebo Trial record or paper	Spleen shrank 27.8% vs grew 2.3% on placebo; platelets up 32% vs down 9%; hemoglobin up 0.7 vs down 0.5 g/dL
Zavesca miglustat (generics available, including Yargesa) Actelion (Johnson & Johnson); generics from several makers	Study 1, 28 adults who could not take enzyme therapy, 12 months, no comparison group	Liver 12% smaller and spleen 19% smaller; hemoglobin change of 0.26 g/dL was not significant

Safety

Gaucher Disease treatment side effects and warnings

Cerezyme, VPRIV and Elelyso carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

Gaucher Disease treatments: most common side effects and key warnings from the FDA labels
Drug	Most common side effects	Key warning
Cerezyme imiglucerase Sanofi (Genzyme)	back pain, chills, dizziness, headache and nausea	Boxed warning Boxed warning for life-threatening allergic reactions including anaphylaxis. Start in a healthcare setting with emergency equipment; people with antibodies to the drug are at higher risk.
VPRIV velaglucerase alfa Takeda	allergic-type infusion reactions 52%, headache 35%, dizziness 22% and fever 22%	Boxed warning Boxed warning for life-threatening allergic reactions including anaphylaxis. Start in a healthcare setting with emergency equipment.
Elelyso taliglucerase alfa Pfizer	headache 19%, joint pain 13%, tiredness 9% and nausea 9%	Boxed warning Boxed warning for life-threatening allergic reactions including anaphylaxis. In its trials 29% of 72 people had an allergic-type reaction and 3% had anaphylaxis; medicine beforehand to prevent reactions may be considered.
Cerdelga eliglustat Sanofi (Genzyme)	joint pain 45%, headache 40%, migraine 10% and nausea 10%	No boxed warning. Can change heart rhythm at high blood levels, so many drug combinations and liver problems rule it out; not recommended with heart disease or long QT syndrome.
Zavesca miglustat (generics available, including Yargesa) Actelion (Johnson & Johnson); generics from several makers	diarrhea 89%, weight loss 39%, gas 29% and headache 21%	No boxed warning. Can cause nerve damage in the hands and feet (neurological exams every 6 months), tremor, diarrhea with weight loss, and lower platelet counts.

Not yet approved

Gaucher disease treatments in Phase 3 or under FDA review

Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.

Gaucher Disease drugs in development
Drug	Status	How it works and is given	Pivotal trial	Result so far	What is next
venglustat Sanofi	Under FDA reviewas of October 12, 2026	Daily pill that slows production of the fatty substance at its source and, unlike Cerdelga and miglustat, is designed to reach the brainTablet by mouth once a day	LEAP2MONO, Phase 3, type 3 Gaucher diseasePrimary endpoint: Brain and body measures in type 3 (Sanofi reports both primary endpoints met) ClinicalTrials.gov	Met both primary endpoints and 3 of 4 key secondary endpoints (Sanofi)	FDA decision due November 25, 2026 under priority review, for type 3 Gaucher disease Sanofi press release, May 28, 2026

Cost

Help paying for Gaucher disease treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Follow Gaucher Disease treatment news by email

One email when the FDA acts on a Gaucher Disease treatment, a label changes or a new trial opens. Never a newsletter.

You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Gaucher Disease. Turn any of these off from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy

Questions

Gaucher Disease treatment questions people ask

Cerezyme vs VPRIV vs Elelyso: what is the difference?

All 3 replace the missing glucocerebrosidase enzyme by IV infusion, usually every 2 weeks, and all 3 carry a boxed warning for severe allergic reactions.

Who it covers: Cerezyme covers adults and children with type 1 and the non-brain symptoms of type 3. VPRIV and Elelyso cover type 1, with dosing set out for age 4 and older.

Infusion time: VPRIV runs 60 minutes, Elelyso 60 to 120 minutes, and Cerezyme 1 to 2 hours.

How made: Elelyso is made in carrot cells, Cerezyme in hamster cells and VPRIV in a human cell line.

Switching: the VPRIV and Elelyso labels describe moving people from Cerezyme at the same dose.

More: Cerezyme, VPRIV and Elelyso drug pages

Source: FDA label for Cerezyme, DailyMed; FDA label for VPRIV, DailyMed; FDA label for Elelyso, DailyMed

Is there a pill for Gaucher disease?

Yes, 2. Both are for adults with type 1 and slow the making of the fatty substance instead of replacing the enzyme.

Cerdelga (eliglustat): a capsule once or twice a day, depending on a CYP2D6 gene test. In its 9-month trial the spleen shrank 27.8% against a 2.3% increase on placebo.

Miglustat (Zavesca and generics, including Yargesa): a capsule 3 times a day, only for mild to moderate type 1 when enzyme replacement is not an option. Diarrhea affected 89% of people in its main study.

More: Cerdelga drug page and miglustat drug page

Source: FDA label for Cerdelga, DailyMed; FDA label for Zavesca, DailyMed

Who can take Cerdelga?

Adults with type 1 Gaucher disease whose CYP2D6 gene test, using an FDA-cleared test, shows they are an extensive, intermediate or poor metabolizer.

Not a fit: ultra-rapid metabolizers, people whose result is indeterminate, and many people taking certain other medicines or with liver problems, because high blood levels can change heart rhythm.

Not recommended: with existing heart disease, long QT syndrome, or some heart rhythm medicines.

More: Cerdelga drug page

Source: FDA label for Cerdelga, DailyMed

Is there a treatment for the brain symptoms of Gaucher disease?

Not yet. No approved drug treats the brain and nervous system symptoms of type 2 or type 3. Cerezyme's label covers type 3, but only its symptoms outside the brain.

Coming next: venglustat, a once-daily pill from Sanofi designed to reach the brain, is under FDA priority review for type 3, with a decision due November 25, 2026. Its Phase 3 trial, LEAP2MONO, met both primary endpoints, according to Sanofi.

More: venglustat FDA decision page

Source: FDA label for Cerezyme, DailyMed; Sanofi, May 28, 2026

Is there a generic for Zavesca?

Yes. Generic miglustat capsules are sold by several makers, including Yargesa from Edenbridge, with the same Gaucher use as Zavesca: adults with mild to moderate type 1 for whom enzyme replacement is not an option. There are no generics of the 3 enzyme infusions or of Cerdelga.

More: miglustat drug page

Source: FDA label for Zavesca, DailyMed

Go deeper

More on Gaucher Disease at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

Cerezyme (imiglucerase) prescribing information, Sanofi (Genzyme), label dated Aug 2026. DailyMed
VPRIV (velaglucerase alfa) prescribing information, Takeda, label dated Nov 2024. DailyMed
Elelyso (taliglucerase alfa) prescribing information, Pfizer, label dated Dec 2025. DailyMed
Cerdelga (eliglustat) prescribing information, Sanofi (Genzyme), label dated Mar 2024. DailyMed. Pivotal trial: ClinicalTrials.gov
Zavesca (miglustat (generics available, including Yargesa)) prescribing information, Actelion (Johnson & Johnson); generics from several makers, label dated Apr 2023. DailyMed
venglustat, Sanofi: ClinicalTrials.gov record; Sanofi press release, May 28, 2026. Checked October 12, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.